A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19

BACKGROUND: Coronavirus disease 19 (COVID-19) is spreading globally and treatment options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a broad-spectrum antiviral treatment candidate, optimized for inhalation and intranasal administration (UNI91104) was developed....

Descripción completa

Detalles Bibliográficos
Autores principales: Backer, Vibeke, Sjöbring, Ulf, Sonne, Jesper, Weiss, Anne, Hostrup, Morten, Johansen, Helle Krogh, Becker, Victoria, Sonne, David P., Balchen, Torben, Jellingsø, Mads, Sommer, Morten Otto Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021896/
https://www.ncbi.nlm.nih.gov/pubmed/33842908
http://dx.doi.org/10.1016/j.lanepe.2021.100084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021896/
https://www.ncbi.nlm.nih.gov/pubmed/33842908
http://dx.doi.org/10.1016/j.lanepe.2021.100084

Ejemplares similares